KURA Kura Oncology Inc.

Kura Oncology to Present at Wedbush PacGrow Healthcare Virtual Conference

Kura Oncology to Present at Wedbush PacGrow Healthcare Virtual Conference

SAN DIEGO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation at the 2020 Wedbush PacGrow Healthcare Virtual Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to present an overview of the company on Tuesday, August 11, 2020 at 2:20 p.m. ET / 11:20 a.m. PT. The virtual conference will be held from August 11-12, 2020.

A live audio webcast of the presentation will be available in the Investors section of Kura’s website at , with an archived replay available for 30 days following the event.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of two wholly owned, small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura’s most advanced drug candidate is tipifarnib, a potent, selective and orally bioavailable farnesyl transferase inhibitor currently in a registration-directed trial (AIM-HN) in patients with recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma. The Company’s pipeline is also highlighted by KO-539, a potent and selective inhibitor of the menin-KMT2A(MLL) protein-protein interaction currently in a Phase 1/2A clinical trial (KOMET-001) in patients with relapsed/refractory acute myeloid leukemia. For additional information about Kura, please visit the Company’s website at .

Contacts

Company:

Pete De Spain

Vice President, Investor Relations &

Corporate Communications

(858) 500-8803

Investors:

Robert H. Uhl

Managing Director

Westwicke ICR

(858) 356-5932

Media:

Jason Spark

Managing Director

Canale Communications

(619) 849-6005

EN
04/08/2020

Underlying

KURAKura Oncology Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Kura Oncology Inc.

David Nierengarten ... (+8)
  • David Nierengarten
  • Dennis Pak
  • Geoffrey Von Der Ahe
  • Laura Chico
  • Martin Fan
  • Ritika Das
  • Robert Driscoll
  • Yun Zhong
RARE ULTRAGENYX PHARMACEUTICAL INC.
MNKD MANNKIND CORP.
KURA KURA ONCOLOGY INC.
CTMX CYTOMX THERAPEUTICS INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
NTLA INTELLIA THERAPEUTICS INC.
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
ARVN ARVINAS HOLDING
RVMD REVOLUTION MEDICINES
PRAX PRAXIS PRECISION MEDICINES
TVTX TRAVERE THERAPEUTICS INC
NUVB NUVATION BIO INC (A)
DAWN DAY ONE BIOPHARMACEUTICALS INC
TNGX TANGO THERAPEUTICS
INC
08/08/25 August 8, 2025 1 EN
Wedbush Research
  • Wedbush Research
GEO GEO GROUP INC. (THE)
WLDN WILLDAN GROUP
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
KURA KURA ONCOLOGY INC.
EXPE EXPEDIA GROUP INC.
CXW CORECIVIC INC.
CTMX CYTOMX THERAPEUTICS INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
SKY SKYLINE CHAMPION CORPORATION
AAPL APPLE INC.
RCKT ROCKET PHARMACEUTICALS
HEAR TURTLE BEACH CORP.
STRO SUTRO BIOPHARMA
PINS PINTEREST INC. CLASS A
DDOG DATADOG INC CLASS A
ACET ADICET BIO INC
CRSR CORSAIR GAMING
PLTK PLAYTIKA HOLDING
TTD THE TRADE DESK
CCSI INC.
JANX CONSENSUS CLOUD SOLUTIONS INC
SOUN JANUX THERAPEUTICS INC
EWTX SOUNDHOUND AI INC
SKLZ EDGEWISE THERAPEUTICS INC
DNTH SKILLZ INC
NATL DIANTHUS THERAPEUTICS INC
OS NCR ATLEOS CORPORATION
ONESTREAM INC
08/08/25 August 8, 2025 1 EN
Geoffrey Von Der Ahe ... (+3)
  • Geoffrey Von Der Ahe
  • Ritika Das
  • Robert Driscoll
KURA KURA ONCOLOGY INC.
08/08/25 August 8, 2025 1 EN
 PRESS RELEASE
Free
KURA Kura Oncology ...

Kura Oncology Reports Second Quarter 2025 Financial Results

Kura Oncology Reports Second Quarter 2025 Financial Results – FDA Priority Review of New Drug Application (NDA) for ziftomenib in adults with R/R NPM1-m AML with Prescription Drug User Fee Act (PDUFA) target action date set for November 30, 2025 – – Fully engaged in commercial readiness activities in alignment with regulatory review timeline – – KOMET-017-IC (intensive chemotherapy) and NIC (non-intensive chemotherapy) phase 3 studies in newly diagnosed AML on track to start in 2H 2025 – – Three clinical abstracts from Kura’s farnesyl transferase inhibitors (FTI) development program acce...

August 7, 2025 1 EN
 PRESS RELEASE
Free
KURA Kura Oncology ...

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635...

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on August 1, 2025, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 646,700 shares of common stock to thirty-five (35) new employees under the Com...

August 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch